850090-13-0

Basic information

• Product Name: Tos-PEG3-t-butyl ester
• Synonyms: Tos-PEG3-t-butyl ester;Tos-PEG2-CH2CH2COOtBu
• CAS NO: 850090-13-0
• Molecular Formula: C₁₈H₂₈O₇S
• Molecular Weight: 388.48
• Mol File: 850090-13-0.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 495.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.159±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Tos-PEG3-t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Tos-PEG3-t-butyl ester(850090-13-0)
• EPA Substance Registry System: Tos-PEG3-t-butyl ester(850090-13-0)

Safety Data

• Hazardous Substances Data: 850090-13-0(Hazardous Substances Data)

Usage

Description

Tos-PEG3-t-butyl ester is a PEG linker containing a t-butyl ester and a tosyl group. The hydrophilic PEG spacer increases solubility in aqueous media. The t-butyl protected carboxyl group can be deprotected under acidic conditions. The tosyl group is a very good leaving group for nucleophilic substitution reactions.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 133803-81-3 2-methyl-2-propanyl 3-[2-(2-hydroxyethoxy)ethoxy]propanoate 
• 1663-39-4 tert-Butyl acrylate 

Downstream Products

• 1312309-63-9 3-(2-(2-azidoethoxy)ethoxy)propanoic acid 
• 1271728-79-0 tert-butyl 3-(2-(2-azidoethoxy)ethoxy)propanoate 
• 1938057-43-2 tert-butyl 3-(2-(2-iodoethoxy)ethoxy)propanoate 
• 1398044-50-2 C₁₁H₂₂O₄S 

Relevant articles and documents

Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing

The delivery of siRNAs to selectively target cells poses a great challenge in RNAi-based cancer therapy. The lack of suitable cell-targeting methods seriously restricts the advance in delivering siRNAs to extrahepatic tissues. Based on prostate-specific m

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.